## Sergii Shevchuk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5100187/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Annals of the Rheumatic Diseases, 2013, 72, 1613-1620.	0.9	575
2	Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology, 2021, 60, 2277-2287.	1.9	36
3	The prevalence and incidence of Systemic Lupus Erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). Lupus, 2014, 23, 213-219.	1.6	29
4	Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial. BioDrugs, 2019, 33, 79-91.	4.6	26
5	Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE). Lupus Science and Medicine, 2015, 2, e000060-e000060.	2.7	7
6	Systemic lupus erythematosus and associated healthcare resource consumption in selected cities from the Russian Federation, Republic of Kazakhstan and Ukraine: the ESSENCE study. Journal of Medical Economics, 2018, 21, 1006-1015.	2.1	4
7	Possibilities of using hemostasis markers and parameters of hemostatic potential for predicting thrombotic complications in patients with CKD stage VD. Reports of Vinnytsia National Medical University, 2019, 23, 677-680.	0.1	2
8	SAT0170â€A NOVEL FORMULATION OF CT-P13 FOR SUBCUTANEOUS ADMINISTRATION: 30 WEEK RESULTS FR A PART 2 OF PHASE I/III RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, ,	20M	0
9	Life quality of men with ankylosing spondylitis: association with the disease course and the structural and functional state of bone tissue. BolÊ <sup>1</sup> , Sustavy, PozvonoÄnik, 2021, 11, 70-78.	0.1	0
10	HORMONAL AND VEGETATIVE FACTORS OF INSULIN RESISTANCE IN PATIENTS WITH HYPERTENSION. Problemi Endokrinnoi Patologii, 2021, 77, 91-98.	0.2	0
11	Bone mineral density in women with systemic lupus erythematosus, its association with bone turnover markers, levels of estradiol and interleukin-6. Polish Annals of Medicine, 0, , .	0.3	0

12 ĐЕЙĐОГĐ£ĐœĐžĐĐĐ>ЬĐІ ĐŸĐĐžĐ**Đ**†Đ>І Đ¢Đ•Đ†ĐĐ<sub>i</sub>Đ£Đ>ІĐĐžĐЕЗĐ<sup>~</sup>Đ<sub>i</sub>Đ¢Đ•ĐĐ¢ĐІĐ<sub>i</sub>Đ¢Đ¬ Đź<u>Đ</u>Đ¥Đ'ĐžĐĐ<sup>~</sup>Đ¥ ĐĐ€